Literature DB >> 25223529

The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.

Danijela Lekovic1, Mirjana Gotic, Natasa Milic, Predrag Miljic, Mirjana Mitrovic, Vladan Cokic, Ivo Elezovic.   

Abstract

The current widely accepted stratification defined by age and previous thrombosis in patients with essential thrombocythemia (ET) probably deserves deeper analysis. The aim of our study was to identify additional factors at the time of diagnosis, which have an impact on the thrombosis prediction. We conducted a study of 244 consecutive ET patients with median follow-up of 83 months. We analyzed the influence of age, gender, laboratory parameters, history of previous thrombosis, spleen size, JAK2 mutation as well as cardiovascular (CV) risk factors including arterial hypertension, diabetes, active tobacco use and hyperlipidemia in the terms of thrombosis. The most important predictors of thrombosis in multivariate Cox regression model were the presence of CV risk factors (p=0.004) and previous thrombosis (p=0.038). Accordingly, we assigned risk scores based on multivariable analysis-derived hazard ratios (HR) to the presence of 1 CV risk factor (HR=3.5; 1 point), >1 CV risk factors (HR=8.3; 2 points) and previous thrombosis (HR=2.0; 1 point). A final three-tiered prognostic model for thrombosis prediction was developed as low (score 0), intermediate (score 1 or 2) and high risk (score 3) (p<0.001). The hazard of thrombosis was 3.8% in low-risk group, 16.7% in the intermediate-risk group and 60% in the high-risk group (p<0.001). Patients with thrombotic complications during the follow-up had a significantly shorter survival (p=0.018). The new score based on CV risk factors and previous thrombotic events allows a better patient selection within prognostic-risk groups and improved identification of the high-risk patients for thrombosis.

Entities:  

Mesh:

Year:  2014        PMID: 25223529     DOI: 10.1007/s12032-014-0231-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

1.  Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Authors:  Alessandra Carobbio; Juergen Thiele; Francesco Passamonti; Elisa Rumi; Marco Ruggeri; Francesco Rodeghiero; Maria Luigia Randi; Irene Bertozzi; Alessandro M Vannucchi; Elisabetta Antonioli; Heinz Gisslinger; Veronika Buxhofer-Ausch; Guido Finazzi; Naseema Gangat; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

Review 2.  Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

Authors:  F Cervantes; F Passamonti; G Barosi
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

Review 3.  Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2012-03       Impact factor: 10.047

Review 4.  Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.

Authors:  Matteo Nicola Dario Di Minno; Antonella Tufano; Walter Ageno; Paolo Prandoni; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2011-04-02       Impact factor: 3.397

5.  Serum lipid levels and the risk of venous thrombosis.

Authors:  Carine J M Doggen; Nicholas L Smith; Rozenn N Lemaitre; Susan R Heckbert; Frits R Rosendaal; Bruce M Psaty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-26       Impact factor: 8.311

6.  Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

Authors:  Francesco Passamonti; Elisa Rumi; Luca Arcaini; Emanuela Boveri; Chiara Elena; Daniela Pietra; Sabrina Boggi; Cesare Astori; Paolo Bernasconi; Marzia Varettoni; Ercole Brusamolino; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2008-09-11       Impact factor: 9.941

7.  Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.

Authors:  Francesca Palandri; Lucia Catani; Nicoletta Testoni; Emanuela Ottaviani; Nicola Polverelli; Mauro Fiacchini; Antonio De Vivo; Federica Salmi; Alessandro Lucchesi; Michele Baccarani; Nicola Vianelli
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

Review 8.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

Authors:  Alexandra P Wolanskyj; Susan M Schwager; Rebecca F McClure; Dirk R Larson; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2006-02       Impact factor: 7.616

10.  Cardiovascular risk factors and venous thromboembolism: a meta-analysis.

Authors:  Walter Ageno; Cecilia Becattini; Timothy Brighton; Rita Selby; Pieter W Kamphuisen
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

View more
  2 in total

Review 1.  The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

2.  Thrombophilic Risk of Factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin Mutations in Essential Thrombocythemia Egyptian Patients.

Authors:  Mohamed S El-Ghonemy; Solafa El Sharawy; Maryan Waheeb Fahmi; Shaimaa El-Ashwah; May Denewer; M A El-Baiomy
Journal:  Adv Hematol       Date:  2020-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.